Too Old to Operate11d
Combatting the Rising Rates of NTM Pulmonary Disease
Updated NTM pulmonary disease estimates in U.S. Medicare beneficiaries revealed rising incidence, demographic disparities, and associated comorbidities.
Yahoo Finance12d
Paratek’s antibiotic succeeds in Phase IIb lung disease trial
in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease. The therapy showed an improvement in at least 50 ...
Hosted on MSN2d
How Nochi Leaves Are Believed To Treat Lung Ailments
The mucus is a common symptom in chronic lung diseases such as COPD ( chronic bronchitis and emphysema), cystic fibrosis, bronchiectasis, NTM lung disease, or asthma. Besides ailments related to lungs ...
Yahoo Finance9d
Positive Phase II top-line data highlights omadacycline’s potential in the NTM market
In a study of 66 adult patients with nontuberculous mycobacteria pulmonary disease (NTM-PD) caused by mycobacterium abscessus ...
The Pharma Letter8d
Paratek Phase IIb results highlight omadacycline’s potential in NTM treatment
USA-based Paratek Pharmaceuticals has released positive top-line data from a Phase IIb trial evaluating its oral antibiotic ...
Positive Outlook for AN2 Therapeutics: Buy Rating Justified by Strategic Pipeline Advancements and Strong Financial Health
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a ...
Pharmabiz12d
Paratek Pharma announces positive top-line data from phase 2b study of oral omadacycline in NTM abscessus pulmonary disease
Paratek Pharma announces positive top-line data from phase 2b study of oral omadacycline in NTM abscessus pulmonary disease: Boston Monday, November 11, 2024, 18:00 Hrs [IST] Para ...